DrAlan Hibbitts

Dr. Alan Hibbitts completed his PhD in the School of Pharmacy at RCSI. Alan joined the Tissue Engineering Research Group (TERG) in the Dept of Anatomy as a post-doctoral researcher in 2013. From 2014-2017, Alan joined the Commissariat à l'énergie atomique (CEA) in Grenoble, France. Re-joining TERG in 2017, Alan worked as a Research Fellow developing materials for nerve repair in conjunction with the AMBER Centre and Integra LifeSciences.

A TERG Principal Investigator since 2018, his research focuses on combating post-surgical inflammation and fibrosis in glaucoma patients. He has accrued €733,590 in direct research funding, supervised multiple undergraduate, MSc and Post-doctoral Researchers and filed patents on research findings. Dr. Hibbitts’ findings have been recognised through multiple research innovation awards. Dr. Hibbitts has published 19 peer reviewed articles (h-index of 12). Dr. Hibbitts is a regular reviewer of journals such as Nature Communications, Science Advances, Advanced Science, Advanced Materials, Scientific Reports etc. Dr. Hibbitts Lectured in the Department of Anatomy & Regenerative Medicine from Feb 2022-April 2023.

In January 2023, Dr. Hibbitts founded LEP Biomedical (www.lepbiomedical.com) which he now leads as CEO. LEP’s goal is to advance his anti-fibrotic platform developed at RCSI to the clinic. Since founding, LEP Biomedical has received the 1st runner up prize from IDEATE Ireland (2023), was shortlisted for the Innovation Award at the 2024 Future Health Summit, won silver in the MedTech category at the 2024 National Start up Awards and was awarded the "Most Ambitious Pharma" award at the Top 100 Most Ambitious Companies in Ireland Awards hosted by Spark Crowdfunding Platform in 2025.